180 related articles for article (PubMed ID: 38541733)
1. Biodistribution Assessment of a Novel
Pavone AM; Benfante V; Giaccone P; Stefano A; Torrisi F; Russo V; Serafini D; Richiusa S; Pometti M; Scopelliti F; Ippolito M; Giannone AG; Cabibi D; Asti M; Vettorato E; Morselli L; Merone M; Lunardon M; Andrighetto A; Tuttolomondo A; Cammarata FP; Verona M; Marzaro G; Mastrotto F; Parenti R; Russo G; Comelli A
Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541733
[TBL] [Abstract][Full Text] [Related]
2. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
4. Automated Synthesis of
Hörmann AA; Plhak E; Klingler M; Rangger C; Pfister J; Schwach G; Kvaternik H; von Guggenberg E
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335396
[TBL] [Abstract][Full Text] [Related]
5. PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.
Roosenburg S; Laverman P; Joosten L; Cooper MS; Kolenc-Peitl PK; Foster JM; Hudson C; Leyton J; Burnet J; Oyen WJ; Blower PJ; Mather SJ; Boerman OC; Sosabowski JK
Mol Pharm; 2014 Nov; 11(11):3930-7. PubMed ID: 24992368
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. A New Preclinical Decision Support System Based on PET Radiomics: A Preliminary Study on the Evaluation of an Innovative
Benfante V; Stefano A; Comelli A; Giaccone P; Cammarata FP; Richiusa S; Scopelliti F; Pometti M; Ficarra M; Cosentino S; Lunardon M; Mastrotto F; Andrighetto A; Tuttolomondo A; Parenti R; Ippolito M; Russo G
J Imaging; 2022 Mar; 8(4):. PubMed ID: 35448219
[TBL] [Abstract][Full Text] [Related]
8. Exploiting the Concept of Multivalency with
Summer D; Rangger C; Klingler M; Laverman P; Franssen GM; Lechner BE; Orasch T; Haas H; von Guggenberg E; Decristoforo C
Contrast Media Mol Imaging; 2018; 2018():3171794. PubMed ID: 29849512
[TBL] [Abstract][Full Text] [Related]
9. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
10. Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK
Nock BA; Kanellopoulos P; Chepurny OG; Rouchota M; Loudos G; Holz GG; Krenning EP; Maina T
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35336041
[TBL] [Abstract][Full Text] [Related]
11. Radiopharmaceutical Formulation and Preclinical Testing of
Hörmann AA; Klingler M; Rangger C; Mair C; Decristoforo C; Uprimny C; Virgolini IJ; von Guggenberg E
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34208516
[TBL] [Abstract][Full Text] [Related]
12. Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.
Pfister J; Summer D; Rangger C; Petrik M; von Guggenberg E; Minazzi P; Giovenzana GB; Aloj L; Decristoforo C
EJNMMI Res; 2015 Dec; 5(1):74. PubMed ID: 26669693
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
14. Improved positron emission tomography imaging of glioblastoma cancer using novel
Loft MD; Sun Y; Liu C; Christensen C; Huang D; Kjaer A; Cheng Z
Amino Acids; 2017 Jun; 49(6):1089-1100. PubMed ID: 28316028
[TBL] [Abstract][Full Text] [Related]
15. Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression.
Summer D; Kroess A; Woerndle R; Rangger C; Klingler M; Haas H; Kremser L; Lindner HH; von Guggenberg E; Decristoforo C
PLoS One; 2018; 13(7):e0201224. PubMed ID: 30059514
[TBL] [Abstract][Full Text] [Related]
16. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
